This method has been used primarily to detect minor airways obstruction, as it is believed that airway closure occurs at higher lung volumes when this is present. It has already been used to study the effects of smoking, and smokers have been shown to have a higher CV/TLC than non-smokers. Dr J V Collins and I are currently studying the effects of bronchodilators on the closing volume in healthy subjects, and we have also examined airway closure in patients with left heart failure. We have been gratified to find that we can obtain a satisfactory Phase 4 in these patients, as can be seen in Fig 2. The method will, however, probably have limitations, particularly when there is marked regional inhomogeneity, and in some patients with asthma there is neither a satisfactory Phase 3 nor a clearly defined Phase. 4. We have,..however,. obtained records from patients with severe asthma which show a progressive improvement towards a normal trace when successfully treated with corticosteroids and this suggests that the method may also prove of value in more severe degrees of airways obstruction.
DISCUSSION
Dr Clark, replying to a question about reproducibility, said that about 50 normal subjects had been studied on anything up to a dozen occasions. The reproducibility of the closing volume both within and between study periods was better than was the case with the vital capacity or FEVL.0.
Dr D H Glaister had used this test both with argon and a mass spectrometer and with xenon and a scintillation detector, and commented that the former method provided a less variable trace, clearer cardiac oscillations and a cleaner break-away. Dr There is no simple answer to the question posed in the title and to respond briefly permits no more than a partial listing and minimal discussion of some of the problems involved. Table 1 provides a list of the considerations in the quest for a 'best' test. They will be taken in order.
(1) What are the requirements for a reliable test ? (a) Validity: It is not entirely clear what it is that the tests for airway resistance measure. This is particularly true in the normal where Section ofMeasurement in Medicine tests of expiratory flow correlate very poorly with each other (Sobol & Emirgil 1968a) . It is equally true of flow rates within the 'effort independent' portion of the expired volume (Sobol & Emirgil 1963) . The poor correlation also holds for measures of expiratory flow and airway conductance (CA) in the normal (Pelzer & Thomson 1966) . In the subject with pulmonary disease, where the causes of diminished airflow may be varied and complex, the measures of flow rate, oddly enough, correlate much more precisely (Sobol & Emirgil 1968a ).
(b) Sensitivity: The best test should have a very narrow range of normal, permitting ready identification of disease when small deviations occur. No existing test fills this requirement. The range of specific conductance (CA/TGV), for example, which was proposed as being fairly constant for all subjects including children (Briscoe & Dubois 1958) , is given by Pelzer & Thomson (1966) and Bouhuys & van de Woestijne (1970) as 0-114 to 0 404 and 0-09 to 0 47 (0-230± 2 s.d.) respectively. A comparable range for serum sodium for the two examples would be 61 to 218 and 55 to 225! (c) Reproducibility: All portions of the expiratory flow curve tend to be poorly reproducible in the normal, there being no advantage to the 'effort independent' portion. A limited experience with the isovolume flow curves was not encouraging (Sobol & Emirgil 1963) . However, the isovolume point should be measured by plethysmography and not be taken from the expiratory volume. But to use such a technique routinely would be very cumbersome. Reproducibility is better in patients than in normals and the first second volume (FEV1) appears most constant in both (Sobol & Emirgil 1968a ).
(2) What is the Purpose ofthe Test ? (a) Detection: This may be the most complicated aspect of the question posed and involves the uncertainty of normal limits and, as a corollary, the number of false positive tests one is willing to accept in exchange for detection of early abnormality. Although the best test for the detection of chronic obstructive pulmonary disease (COPD) has not been identified, some negative observations can be made. Measurements of airway resistance (RA) or CA/TGV are not sensitive to early changes (Mitchell et al. 1967 ).
Our experience has been similar. In our hands the FEV1, although most reproducible, is also not very useful for early detection. The maximal mid-expiratory flow (MMF) (Leuallen & Fowler 1955 ) is very useful for early detection, as is the first second percentage (FEV1%) of the FVC. The former has the advantage that it has the largest percentage fall from predicted of any flow measurement (Emirgil & Sobol 1971 ) so that large changes occur early. The FEV1 % is also useful if one applies stringent criteria and if the predicted normal is predicted on age, sex and FVC (Sobol & Emirgil 1964) . The use of a single lower limit of normal such as 60%, 70% or even 75 % is invalid and much too insensitive.
(b) Acute response to therapy: For all practical purposes this is limited to the response to bronchodilators. Since the forced vital capacity (FVC) will commonly increase following bronchodilatation, the volume-dependent measures of flow such as the MMF and FEV1 % are not useful, although Olsen & Hale (1968) have suggested a volume correction method for the MMF. In asthma the FVC and/or FEV1 are the most useful measures of expiratory flow (Sobol et al. 1970) . RA is a very sensitive index of response but has the drawback that the response in normals is not well known. This makes the response in a suspected asthmatic with a normal RA uncertain. There is little if any merit in correcting RA to CA/TGV in asthmatics (Sobol et al. 1970) . The response to bronchodilator in COPD is very variable and changes in plethysmography and expiratory flow may occur one without the other.
(c) Course: In our hands the course of COPD is best determined by the MMF (Emirgil & Sobol 1971 ). RA and CA/TGV give a poor indication of the course. In a group of 38 subjects with COPD with a mean follow up of 3 years, the mean decline in MMF and FEVY gave P=0-001, while for CA and CA/TGV P was only >0 4 and >09 respectively.
(d) Differentiation: No attempt is made to differentiate bronchitis and emphysema in my laboratory. Although this may be possible and even useful in separating groups of patients, it has not proved useful in the individual case. Without the measurement of compliance it would be difficult to separate these two groups. Even with this measurement there are inconsistencies. For example, the patients of Penman et al. (1970) with low retractive force and normal airway resistance (emphysema) had a more nearly normal CA/TGV than did those with normal retractive force and high airways resistance (bronchitis). The relationship of RA to CA/TGV does not appear useful for separating emphysema from bronchitis. Furthermore, most patients have mixed disease so that separation is not truly possible in most instances. The suggestion that large and small airway resistance can be distinguished by the relationship of RA to expiratory flow (Bouhuys & Woestijne 1970) noted in byssinosis workers does not find a counterpart in a routine service laboratory. Normal airway resistance with diminished expiratory flow (obstruction of the small airways) may result from a loss of retractive force. Increased airway resistance with normal expiratory flow (large airway obstruction) is rarely seen in my laboratory.
'Which test is best?' remains to be answered. However, the observations noted above merit some conclusions. Body plethysmography is not useful for early detection or for following the course of COPD. It is probably the most sensitive for detecting bronchodilatation in asthmatics. In COPD plethysmography and expiratory flow measurements are both necessary since patients with COPD may respond to one test but not the other. For early detection the MMF and FEV1 %, properly used, are the best. Finally, I would make a plea that single criteria for the lower limit of normal should not be used for any test, but that the subject's size, sex, age, &c., should be used in predictions. Early detection, even in mild COPD, may then be possible.
Dr C B McKerrow commented that surveys in this country had shown the fall in the FEV on longitudinal studies of individuals to be smaller than that expected from cross-sectional study of people who spanned those years. He wondered if there was any comparable information on the MMF. Dr Sobol replied that the MMF, unlike the FEV, did not vary with age but"varied with forced vital capacity. Dr L Capel thought that, compared with the FEV, the MMF was a more certain means of identifying patients with early airways obstruction in that once reduced it tended to stay 'down, whereas the FEV fluctuated. But possibly the variations in the FEV1.0 were more informative than the stability of the MMF. Dr Sobol replied that one had to decide how many false positives one was willing to accept. The MMF had the largest percentage fall of any test, down to less than 10% of that predicted. In contrast,1for'timed vital capacity a big fall was to 50% of that predicted, and for FEV1o. to 25%. If the MMF was followed in a patient over a period of years it would still undulate, but about a lower and lower value. Dr P Howard referred to studies he had made of the FEVO.75 with the subject exhaling from total lung capacity against a Starling resistor. The results showed that functionally the airways of patients with asthma, emphysema and bronchitis behaved in much the same way, and he questioned whether pressure flow curves yielded more information than the timed FEV. Dr N Pride commented that differences in the results obtained by the several tests contained a physiological message. For example, in patients with progressive airway disease, the fact that in the early stages the MMF or the flow at 50% vital capacity dropped more than the FEVY1. was related to the underlying mechanism. Dr P Forgacs presented a summary of his investigations into the use which might be made of measurements of sound intensity when a patient breathed through a pneumotachograph (for details see P Forgacs, A R Nathod & H D Richardson (1971) Thorax 26, 288).
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